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Abstract
Background: BRCA1 and BRCA2 mutations confer a substantial breast risk of developing breast cancer to those who
carry them. For this reason, the United States Preventative Services Task Force (USPSTF) has recommended that all
women be screened in the primary care setting for a family history indicative of a mutation, and women with
strong family histories of breast or ovarian cancer be referred to genetic counseling. However, few high-risk women
are being routinely screened and fewer are referred to genetic counseling. To address this need we have
developed two decision support tools that are integrated into clinical care.
Method: This study is a cluster randomized controlled trial of high-risk patients and their health care providers.
Patient-provider dyads will be randomized to receive either standard education that is supplemented with the
patient-facing decision aid, RealRisks, and the provider-facing Breast Cancer Risk Navigation Toolbox (BNAV) or
standard education alone. We will assess these tools’ effectiveness in promoting genetic counseling uptake and
informed and shared decision making about genetic testing.
Discussion: If found to be effective, these tools can help integrate genomic risk assessment into primary care and,
ultimately, help expand access to risk-appropriate breast cancer prevention options to a broader population of
high-risk women.
Trial registration: This trial is retrospectively registered with ClinicalTrials.gov Identifier: NCT03470402: 20 March
2018.
Keywords: Breast Cancer prevention, Decision support, Risk communication, Genetic testing
Background
Breast and ovarian cancers confer significant morbidity and
mortality to women in the United States, and their develop-
ment is strongly influenced by genetic predisposition [1, 2].
Hereditary breast and ovarian cancer syndrome (HBOC) is
an inherited condition that is most often associated with
mutations in the BRCA1 and BRCA2 (BRCA1/2) genes [3].
Carriers of these pathogenic mutations face a lifetime breast
cancer risk of 60–80% and a lifetime ovarian cancer risk of
20–40% [4]. Inherited BRCA1/2 mutations account for an
estimated 2–7% of breast cancers and 10–15% of ovarian
cancers [3, 5, 6]. Approximately one out of every three to
four hundred individuals in the general population carry a
BRCA1/2 mutation [7].
While mutation carriers are at a substantially higher
risk for developing breast and ovarian cancers than the
general population, preventative actions can reduce a
carrier’s cancer risk by up to 90% once she is identified
[8]. Such risk-reducing strategies include intensive breast
cancer screening with mammography and breast MRI,
[9–11] risk-reducing surgeries (prophylactic mastectomy,
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bilateral salpingo-oophorectomy [BSO]), [12–18] and
chemoprevention [19, 20]. Risk-reducing BSO among
women with known BRCA1/2 mutations is further asso-
ciated with a reduction in cancer-specific and all-cause
mortality [15, 18].
In order to promote the identification of women
carrying BRCA1/2 mutations, the United States Pre-
ventive Services Task Force (USPSTF) recommends
that primary care providers screen asymptomatic
women for an increased BRCA1/2 mutation risk [21].
Women who screen positive should receive genetic
counseling by a trained health care provider and be
offered BRCA1/2 testing if further indicated and de-
sired after counseling [21].
The identification of women whose family history
indicates an increased risk for carrying a mutation is
based upon a set of “red flags” in the woman’s med-
ical history and that of her family. These red flags in-
clude early onset of breast or ovarian cancer, multiple
cases of breast or ovarian cancer in the family, bilat-
eral breast cancer, male breast cancer, Ashkenazi
Jewish decent (1 in 40 prevalence of BRCA1/2
founder mutations), or a previously identified BRCA1/
2 mutation in the family [7].
Despite the USPSTF recommendation and the in-
creasing availability of genetic testing for hereditary
cancer syndromes, many women who are at an in-
creased risk of carrying BRCA1/2 mutations are never
identified and are thus unable to receive downstream
preventive services [22–25]. In 2016, our research
team screened 3055 women who underwent mammo-
graphic screening at a large, urban institution [26].
Based on their family histories of breast and ovarian
cancer, 12% (n = 369) of these women met USPSTF
guidelines for BRCA1/2 genetic testing. Nevertheless,
only 4.6% (n = 17) of those eligible women had re-
ceived testing or counseling. Bellcross et al. have re-
ported similar under-utilization of genetic testing
services in another health system [22]. In a large sam-
ple of women unaffected with breast cancer seen in
the primary care setting, 5% met USPSTF guidelines
for genetic counseling. Although 91% of these
high-risk women reported that they had talked to
their health care provider about their family history,
only 14% were referred for genetic counseling, and
only 4% received BRCA1/2 genetic testing.
While the prevalence of BRCA1/2 mutations is
similar across most racial and ethnic groups (except
Ashkenazi Jews), women from racial/ethnic minority
groups and lower education and income levels are less
likely to be referred for genetic testing [22, 27, 28]. This
lack of risk assessment in minority populations can
contribute to further health dipartites and poorer clinical
outcomes [29].
Providers find it difficult to assess breast cancer risk
and communicate probabilistic risk information to their
patients during the primary care encounter [30]. Barriers
to family history screening and genetic counseling refer-
ral include insufficient knowledge of HBOC and inability
to intuit risk, [31–35] lack of time and competing priorities
in the primary care encounter, [30, 36] and inadequate
reporting of family history in medical records [26, 37].
Patient barriers to discussing and understanding risk in-
clude lack of knowledge, low health literacy or numeracy,
language barriers, and time constraints [30, 38, 39].
Further research is needed to determine how breast can-
cer knowledge, the concept of risk—including both gen-
eral and personalized risk information—and the pros and
cons associated with genetic testing are best communi-
cated to women and their providers in order to inform
genetic testing decisions and promote risk-appropriate
prevention strategies. Improving a patient’s knowledge of
breast cancer and genetic testing and the accuracy of her
risk perceptions may help her make a more informed
choice about pursuing HBOC genetic counseling and test-
ing. Integrating specific and actionable risk information
into the clinical encounter may help enable providers to
conduct appropriate risk assessments and refer high-risk
patients to further testing and downstream services.
Methods and design
Aims
The study goal is to expand genetic testing for HBOC to
a broader population of high-risk women by prompting
appropriate referrals from the primary care setting with
the use of an electronic health record-embedded breast
cancer risk navigation (BNAV) tool [40, 41]. To address
patient-related barriers to genetic testing, we developed
a web-based decision aid, RealRisks, [42, 43] which is de-
signed to improve genetic testing knowledge, accuracy
of breast cancer risk perceptions, and self-efficacy to en-
gage in a collaborative dialogue about genetic testing.
Specifically, our aim is to conduct a cluster randomized
controlled trial to evaluate the effect of patient education
with RealRisks and BNAV compared to patient education
alone on promoting appropriate uptake of BRCA1/2
genetic counseling. Secondarily, we will assess the effi-
cacy if the RealRisks/BNAV intervention with measures
of decision process and quality as endpoints.
Population
This study is being conducted in the outpatient clinics of
Columbia University/New York Presbyterian Hospital in
New York, NY. These clinics serve about 42,000 adults
each year [44]. About 70% of the patients seen at these
clinics identify as Hispanic, many from the Dominican
Republic and other parts of the West Indies/Caribbean
Basin [44]. The majority of patients are covered by
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Medicaid [44]. We have found that among patients who
meet family history criteria for BRCA1/2 genetic testing,
less than 5% have undergone HBOC genetic testing due to
the lack of systemic family history screening [26].
The study clinics provide a range of services, including
internal medicine, family medicine, gynecology, and fam-
ily planning. We will engage providers and patients from
each of these specialties.
To be eligible, a provider must be a physician, nurse
practitioner, physician assistant, or nurse midwife who
sees patients in the study clinics and is willing and able to
provide informed consent. Patients must see a provider
enrolled in the study, be 21 to 75 years of age, have no
personal history of breast or ovarian cancer, have never re-
ceived genetic counseling or testing for HBOC, meet fam-
ily history criteria for BRCA1/2 genetic testing based upon
a validated family history screener, [27] and be able to pro-
vide informed consent in English or Spanish.
Cluster randomization
Because this study focuses on patient-provider dyads, we
will cluster randomize the patients at the provider letter.
We will first recruit health care providers, and, upon
consenting, these providers will be given a baseline sur-
vey and then randomized into either the intervention or
control group.
These providers’ patients will then be screened to de-
termine eligibility for the study and for BRCA1/2 testing.
Those who meet eligibility criteria will be recruited and
assigned to the same randomization group as their pro-
vider. In this way, the patients grouped by provider will
form the clusters in this randomized controlled trial.
Study intervention
The study intervention includes the patient-facing Real-
Risks decision aid coupled with the provider-facing BNAV
toolbox. These user-centered tools are integrated into
clinical workflow, were designed with consistent feedback
from members of our target populations, and have been
demonstrated to be useable and appropriate [42, 45].
RealRisks incorporates constructs from shared decision
making and self-determination theory to model
patient-provider dialog, communicate numeric concepts
central to risk, and engage women in deciding upon a
preference-sensitive course of action regarding genetic
testing [46, 47]. RealRisks was designed to incorporate a
patient’s preferences and values in order to improve ac-
curacy of risk perceptions and promote self-efficacy in a
way that will support autonomous decision making.
Specifically, RealRisks was designed to improve genetic
testing knowledge, accuracy of breast cancer risk percep-
tions, and self-efficacy to engage in a collaborative dia-
logue about breast cancer risk and genetic testing.
To accomplish this, RealRisks first provides general
education using a narrative in which a fictitious charac-
ter named Rose discusses breast cancer risk, family his-
tory, and cancer prevention options with friends, family,
and health care providers. Patients can choose to read
this narrative in English or Spanish and in graphic novel
format (narrative light) or slide presentations (narrative
dense). The patient reinforces this information by play-
ing experience-based, pictographic risk games that are
embedded into the education modules (Fig. 1).
Next, the patient is instructed to enter her family history
data into a family tree. RealRisks uses this data to run the
BRCAPRO model, which calculates the patient’s personal-
ized five-year breast cancer risk, lifetime breast cancer risk,
and probability of carrying a BRCA1/2 mutation [48, 49].
This information is then presented to the patient through
another set of experience-based, pictographic risk games.
Finally, RealRisks elicits the patient’s preferences for
pursuing BRCA1/2 genetic testing. This preference elicit-
ation includes the patient’s intention to undergo genetic
testing as well as the factors that were important to her in
making this decision. Examples of such factors include the
increased ability to prevent getting cancer, ease of mind if
the test result is negative, costs associated with testing,
and privacy or discrimination concerns.
This information is then all summarized for the pa-
tient in the Patient Action Plan (Fig. 2), and she is en-
couraged to bring this action plan to her next
appointment with her health care provider.
Once RealRisks calculates risks scores based on the pa-
tient’s family history data, this information is synchronized
into the BNAV toolbox for providers. This risk information
is displayed in a table that includes the patient’s personalized
risk and preference information for each of the provider’s
participating patients. In addition, BNAV uses this risk data
to create a Provider Action Plan, which is similar to the Pa-
tient Action Plan but more succinctly focuses on the pieces
of information that are directly actionable. Figure 3 provides
an example of the table summarizing patient risk profiles in
BNAV, and Fig. 4 provides an example of the Provider
Action Plan.
In order to fully prepare the provider for an informed
discussion during the patient’s clinic visit, BNAV also
provides educational modules on topics such as genetic
testing, patient-centered care, and prevention options
for BRCA1/2 mutation carriers. These educational mod-
ules link to the evidence base that supports the covered
topics in order to increase provider knowledge about
genetic testing and facilitate shared decision making
about a genetic counseling referral.
Finally, the personalized risk information calculated by
RealRisks is further integrated into clinical workflow
through an alert that appears in the EHR-embedded
dashboard used by the institution. This alert flags the
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patient as eligible for genetic testing and provides her
five-year breast cancer risk. Figure 5 provides an ex-
ample of this EHR-embedded dashboard alert.
Control group
All participating patients will receive educational mate-
rials that include a brochure from our institution’s breast
cancer prevention clinic and standard educational mate-
rials from the Susan G. Komen foundation on genes and
breast cancer. Additionally, all patients will receive a
letter that informs them of their eligibility for BRCA1/2
genetic testing, outlines breast and ovarian cancer pre-
vention options, and encourages them to discuss referral
to genetic counseling with their health care provider.
For providers, all enrolled patients will be flagged by the
EHR-embedded dashboard alert.
Study procedure
After providing informed consent, all patients will
complete a baseline survey and then be sent the
Fig. 2 Example summaries provided by the Patient Action Plan
Fig. 1 Example of an experience-based, pictographic risk game in RealRisks
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Fig. 3 Example of the personalized patient table included in the BNAV Toolbox
Fig. 4 Example of the Provider Action Plan
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standard educational materials and eligibility letter. If
the patients are in the intervention group, they will also
receive a letter with instructions for accessing the Real-
Risks decision aid. Upon completing RealRisks, interven-
tion patients will be encouraged to print their Patient
Action Plan and bring it to their upcoming clinical ap-
pointments. All patients will complete another survey
within 2 weeks of the date they are sent the educational
materials or complete RealRisks, depending on the
randomization arm to which they are assigned.
We will make appointments with our institution’s
community resource center for patients who lack com-
puter access. During these appointments, a member of
the study team will assist the patient in accessing Real-
Risks and printing her action plan. Similarly, the study
team will conduct phone interviews for participants who
are not comfortable or able to self-administer the online
questionnaires.
One week prior to an enrolled patient’s clinic visit,
providers randomized into the intervention arm will be
sent this patient’s Provider Action Plan and encouraged
to visit the BNAV toolbox.
All patients and providers will complete additional
questionnaires after their clinical encounter and at 6
months after baseline.
Outcome measurement
The study’s primary endpoint is the appropriate uptake
of HBOC genetic counseling, as assessed by electronic
health record review at 6 months. Secondarily, we will
assess the decision support tools’ effect on measures of
decision quality, such as informed choice, decision con-
flict, and shared decision making. We will also explore
which decision antecedents, such as genetic testing
knowledge, breast cancer risk perceptions and worry,
and decision self-efficacy, have an effect on these
outcomes.
Table 1 provides a table outlining the measurement
scales used at each evaluation. The primary and second-
ary outcomes of interest are also described below.
Primary outcome
Genetic counseling uptake at six months Six months
after a patient is sent the educational materials with or
without RealRisks, we will determine whether or not she
has undergone genetic counseling by examining her
medical record.
In order to avoid long wait times for genetic counsel-
ing appointments serving as a barrier to genetic counsel-
ing uptake, we have coordinated with our institution’s
genetics clinic to ensure that study participants are seen
within a few weeks of referral. We ask patients directly if
they have undergone genetic counseling in the
six-month questionnaire. We also ask providers if they
choose to refer the patient to genetic counseling in their
post-visit questionnaire.
Secondary outcomes
Informed choice We will use the Multidimensional
Measure of Informed Choice to determine whether a pa-
tient has made an informed decision to pursue BRCA1/2
genetic testing [50]. An informed choice is classified as
Fig. 5 Example of the electronic health record (EHR)-embedded dashboard notice
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one that is made with adequate knowledge and that is
consistent with the respondent’s attitudes. In this way,
two groups are classified as having made an informed
choice: 1) those who have adequate genetic testing
knowledge score (> 50% correct) using a validated meas-
ure consisting of 11 true/false questions, [51] have a
positive attitude towards testing according to our Likert
scale attitude measure, which was adapted from the atti-
tude measure used by Marteau et al., [50] and who de-
cide to undergo testing 2) those with adequate genetic
testing knowledge, a negative attitude towards genetic
testing, and who decide not to undergo testing. We will
use the knowledge and attitude scores collected after the
clinical encounter and at 6 months to calculate informed
choice, and we will assess differences between the inter-
vention and control groups.
Decision conflict We will use the low-literacy version
of the Decision Conflict Scale to measure the degree of
personal uncertainty that a patient experiences regarding
the decision to undergo genetic testing [52, 53]. We will
measure decision conflict among patients at baseline,
1 month, after the clinical encounter, and 6 months.
Changes in decision conflict will be compared between
the intervention and control groups.
Shared decision making We will assess the extent to
which the decision to undergo genetic testing actively
involves both the patient’s and provider’s preferences
and values by assessing shared decision making among
patients, using the SDM-Q9, [54] and providers, using
the SDM-Q-DOC, [55] after the clinical encounter. We
Table 1 Measures and Schedule of Evaluation
Patient Evaluations Baseline Post RealRisks or Educational Material Post-Visit 6 M
Demographics X
Literacy [56] X
eHealth Literacy [57] X
Subjective Numeracy [58] X
Acculturation [59] X
Interest in Genetic Testing [71] X
Preparation in Decision Making X X
Perceived Breast Cancer Risk [60] X X X X
Breast Cancer Worry [72] X X X X
Genetic Testing Knowledge [51] X X X X
Genetic Testing Attitudes [50] X X X X
Decision Self-Efficacy [73] X X X
Decision Conflict [52] X X X X
Genetic Testing Decision X X X
RealRisks/Education Material Comments X
Shared Decision Making [54] X
Trust in Health Care Providers [61] X
Decisional Regret [74] X X
Self-Reported Uptake of Genetic Counseling X
Provider Evaluations Baseline Post-Visit 6 M
Demographics X
Subjective Risk Communication Confidence [62] X
Confidence in Managing Patients w/ a Family History of Breast/Ovarian Cancer [63] X X
Genetic Testing Knowledge [64] X X
Genetic Testing Attitudes [75] X X
Subjective Norms [65] X X
Perceived Behavioral Control [65] X X
Behavioral Intention [65] X X
Orientation Towards Shared Decision Making [66] X X
Shared Decision Making [55] X
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will compare differences in shared decision making be-
tween the intervention and control groups.
Exploratory mediating/moderating factors
We will also explore whether an array of decision ante-
cedents have any mediating or moderating effects on the
primary or secondary outcomes. The patient characteris-
tics that we will explore include the following: demo-
graphics, health literacy, [56, 57] numeracy, [58]
acculturation, [59] perceived breast cancer risk and ac-
curacy of risk perceptions, [60] breast cancer worry, gen-
etic testing knowledge, [51] attitudes, [50] self-efficacy in
decision making, [52] preparation in decision making,
and trust in health care providers [61].
The provider measures that we will evaluate include
the following: demographic and professional/practice
characteristics, subjective risk communication confi-
dence, [62] confidence in managing patients with a fam-
ily history of breast or ovarian cancer, [63] genetic
testing knowledge, [64] attitudes, [65] subjective norms,
[65] perceived behavioral control, [65] behavioral
intention, [65] and orientation towards shared decision
making [66].
Sample size calculation and statistical methods
Our goal is to recruit 76 providers and a total of 190
women. With a total sample size of 190 women (95 per
arm), assuming a two-sided Type 1 error of 5%, a 20%
drop-out rate (effective sample size of 76 per arm), and
an intracluster correlation of less than 0.2, we will have
greater than 90% power to detect a difference of a 5%
rate of appropriate genetic counseling in the control arm
(based upon our pilot data) and 30% in the RealRisks/
BNAV intervention arm. We will have 80% power to de-
tect an effect size of .50 difference on decisional conflict
scores between the intervention and control arms, as-
suming a two-sided p-value set at 0.05 and an intraclus-
ter correlation of less than 0.1. Based on previous
studies, this effect size (mean difference/standard devi-
ation) is judged clinically important because effect sizes
observed between those who make and those who delay
decisions have ranged between 0.43 and 0.82 [67].
Agreement between patients’ and providers’ SDM-Q-9
and SDM-Q-Doc scores will be measured using the
intraclass correlation coefficient (ICC) procedure, based
upon the analysis of variance and the estimation of vari-
ance components. The higher the magnitude of this co-
efficient (range, − 1 to 1), the better the absolute match
between the patient’s and provider’s scores.
Comparisons between the intervention and control
groups will be conducted using Chi-square tests for cat-
egorical variables and Student’s t-tests for continuous
variables. After generating descriptive statistics, we will
conduct bivariate analyses using Chi-Square tests,
t-tests, and Pearson correlation coefficients to determine
associations between study variables and genetic coun-
seling uptake rate. Depending on the scale of each out-
come variable (continuous or binary) and the scale of
the independent variable (categorical or continuous), we
will use ANOVAs, linear regression, logistic regression,
variance components analysis, mixed models, and gener-
alized estimating equations (GEE) to identify variables
that are associated with each outcome.
Trial status
We have begun recruiting and enrolling both patients
and providers into the trial. After 5 months of recruit-
ment and engagement, we have enrolled over 50 health
care providers and 20 patients.
This trial is registered retrospectively in clinicaltrials.-
gov under trial number NCT03470402: 20 March 2018.
Discussion
BRCA1/2 mutations are the strongest known breast can-
cer risk factors, conferring up to a 60–80% lifetime risk of
breast cancer among female carriers [4]. While this risk is
significant, mutations in the BRCA1 and BRCA2 genes are
actionable once identified. Cancer prevention options can
reduce breast cancer risk by up to 90% [8] and all-cause
mortality by up to 77% [16, 18]. Identifying those who are
at increased risk of carrying a mutation and facilitating
their access to genetic counseling and testing has the po-
tential to significantly alleviate the public health burden of
hereditary breast and ovarian cancers. For this reason, the
USPSTF has recommended that primary care providers
screen asymptomatic women for a family history indica-
tive of a BRCA1/2 mutation [21].
Nevertheless, while incorporating efficient family his-
tory screening into clinic workflow is critical to identify-
ing patients eligible for BRCA1/2 testing, collecting
detailed family history is time consuming and difficult.
We have found that providers at our institution often re-
port insufficient time to complete a comprehensive fam-
ily history intake or risk assessment during the clinical
encounter, particularly when the patient presents with
ongoing comorbidities that need to be managed [40].
While recruiting primary care providers into this trial,
many were enthusiastic because they understood the im-
portance of collecting and analyzing hereditary cancer
information yet lacked the time to conduct such an as-
sessment themselves. This lack of data collection is likely
the principal reason behind our previous work’s finding
that family history data is insufficiently recorded in our
institution’s electronic health records [26].
RealRisks and BNAV have the potential to addresses
this issue by aiding a patient in collecting her family his-
tory data, clarifying her values, and deliberating her
choice to seek genetic testing before she sees her
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provider during her clinical visit. By doing so, RealRisks
and BNAV can help to ensure that both the patient and
her provider are better prepared to make a shared and
informed decision about BRCA1/2 genetic testing while
reducing the time burden this conversation would nor-
mally bestow upon the rest of the clinical encounter.
This intervention may also have the potential to alleviate
some of the disparities posed by the proliferation of preci-
sion prevention and genomic medicine. Although the
prevalence of BRCA1/2 mutations is comparable among
most racial/ethnic groups except Ashkenazi Jews, racial/
ethnic minorities and women from lower education or in-
come levels are less likely to be referred to and receive
genetic testing for these mutations [27, 28, 34, 68]. As ad-
vances in technology and genomic medicine lead to new
innovations in cancer prevention, it is important to ensure
that these innovations are accessible to all high-risk indi-
viduals in order to reduce health disparities. This study
can help make progress in achieving this goal by evaluat-
ing tools that were designed to incorporate hereditary
breast cancer risk assessment into routine primary care
and to promote knowledge, accuracy of risk perceptions,
and informed decision making in a diverse community
with a high proportion of under-served, low-numerate,
and high-risk patients.
The American Society for Clinical Oncology recom-
mends that all oncology providers use family history in-
formation to inform clinical decision making [69]. While
this recommendation underscores the importance of
family history data in patient care, the data’s utility for
prevention will remain limited if such risk assessments
are only adopted by oncology specialists. RealRisks and
BNAV can help to promote such practices in primary
care by communicating risk information in a way that is
integrated into clinic workflow. Furthermore, this study’s
focus on patient-provider dyads in a diverse primary care
setting—including various types of physicians and phys-
ician extenders practicing in internal medicine, family
medicine, and gynecology—can help expand our under-
standing of how best to promote appropriate referrals
for BRCA1/2 genetic counseling from the primary care
setting.
Additionally, as genetic testing services are becoming
increasingly accessible and affordable, the patient prep-
aration provided by RealRisks may allow for the more ef-
ficient use of genetic counseling and testing services by
providing genetic counselors with a pre-collected and
detailed pedigree.
Finally, while DAs are often shown to be efficacious in
improving knowledge, risk perceptions, and decision
confidence, they are insufficient in and of themselves in
incorporating decision-making about genetic testing in
the clinic [70]. In order to increase our tools’ adoptabil-
ity and effectiveness, we have worked to integrate them
into clinical workflow and existing clinical systems. The
printable Patient Action Plan provides the patient with a
tangible product that she can use to assert her decision
making into the clinical encounter. The Provider Action
Plan is sent to the provider via secure health message
(SHM) before the patient’s clinical encounter. This
prompts and prepares the provider for discussing genetic
counseling with the patient, and the SHM ensures that
the action plan’s patient-derived data is accessible through
the institution’s EHR system. The EHR-embedded dash-
board alert serves a similar purpose in prompting the pro-
vider and incorporating risk information into existing
clinical tools. We are currently working on further inte-
grating RealRisks with existing EHRs by developing a Fast
Healthcare Interoperability Resources-standard applica-
tion programing interface (FHIR API) to prepopulate risk
information in RealRisks and return patient-derived data
to the medical record.
Our future and related work focuses on ensuring ac-
cess to proper downstream, risk management services,
including psychosocial support, for patients with positive
genetic test results.
In conclusion, we have developed informatics-based
tools which collect, analyze, and communicate patient
risk information in order to provide tailored educational
resources to patients and their providers. These tools
have the potential to mitigate common patient and pro-
vider barriers to breast cancer risk assessment and pre-
vention. We are currently evaluating these tools’
effectiveness among patient and provider clusters in
various primary care practices that serve a large and di-
verse patient population. We hope the results from this
trial will help to inform the future implementation of
personalized breast cancer prevention efforts.
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